Treatment of Sporotrichosis in Meningeal Sporotrichosis

Meningeal sporotrichosis represents a serious presentation in which sporotrichosis involves the meninges. This clinical scenario calls for a specific, evidence-based treatment approach that differs from less severe forms of the disease.

Clinical scenario: Patients with meningeal sporotrichosis — where the infection has extended to meningeal involvement — require prompt, structured antifungal management guided by established evidence-based recommendations.

Treatment approach (partial)

Management begins with an intravenous antifungal induction phase, followed — once the patient responds — by oral antifungal step-down therapy to complete a prolonged total course. The full sequencing, agent selection, and duration are detailed in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1086/522765

Amphotericin B, given as a lipid formulation at a dosage of 5 mg/kg daily for 4–6 weeks, is recommended for initial treatment of meningeal sporotrichosis (B-III).
Amphotericin B deoxycholate, administered at a dosage of 0.7–1.0 mg/kg daily, could also be used but was not preferred by the panel (B-III).
Itraconazole administered at a dosage of 200 mg twice daily is recommended as step-down therapy after the patient responds to initial treatment with amphotericin B and should be given to complete a total of at least 12 months of therapy (B-III).

View source ↗